{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:19:26Z","timestamp":1784697566489,"version":"3.55.0"},"reference-count":32,"publisher":"Rambam Health Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"abstract":"<jats:p>Background and Objective: Medical cannabis is becoming an acceptable treatment modality in medicine, especially for pain relief. Concurrently, cannabis use is becoming more prevalent worldwide, a public demand-driven trend despite the lack of established scientific basis. This observational open-label study sought to investigate the effectiveness of cannabis therapy for alleviating low back pain symptoms.  Methods: Two types of cannabis treatment modalities were sequentially administered to chronic low back pain patients. After an initial 1-month washout period (WO1), the first modality was cannabidiol (CBD)-rich sublingual extract treatment administered for 10 months. Following another washout period, the second modality, \u0394\u2079-tetrahydrocannabinol (THC)-rich smoked inflorescence (whole dried cannabis flowers) was administered for 12 months.  Results: Enrolled in the study were 24 patients whose advanced imaging studies (i.e. computerized tomography or magnetic resonance imaging of the lumbar spine) revealed disc herniation or spinal stenosis. Three patients dropped out of extract therapy treatment but resumed study participation to receive THC-rich smoking therapy. After a minimum of 2 years, cannabis therapy had reduced lower back pain symptoms, as assessed by Oswestry Disability Index, the SF-12 patient-reported outcome questionnaire, and the visual analogue scale. Pain reduction was not significant during the extract treatment part of the study; however, pain reduction was significant during the inhaled therapy part of the study.  Conclusions: Our findings indicate that inhaled THC-rich therapy is more effective than CBD-rich sublingual extract therapy for treating low back pain and that cannabis therapy is safe and effective for chronic low back pain.<\/jats:p>","DOI":"10.5041\/rmmj.10485","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T07:25:02Z","timestamp":1666855502000},"page":"e0026","source":"Crossref","is-referenced-by-count":10,"title":["Comparing Sublingual and Inhaled Cannabis Therapies for Low Back Pain: An Observational Open-Label Study"],"prefix":"10.5041","volume":"13","author":[{"name":"Department of Orthopedics, Hasharon Hospital, Rabin Medical Center, Petah Tikva, Israel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Behavioral Neurobiology Laboratory, Department of Occupational Therapy, Faculty of Social Welfare and Health Sciences, The University of Haifa, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Orthopedics, Hasharon Hospital, Rabin Medical Center, Petah Tikva, Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2983","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2165\/00003495-200060060-00005","article-title":"Cannabinoids in clinical practice","volume":"60","author":"EM","year":"2000","unstructured":"1. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000;60:1303-14.","journal-title":"Drugs"},{"key":"ref1","unstructured":"2. Medical Cannabis Unit of the Israel Ministry of Health. Current data from patient licenses - February 2022 [Hebrew]. Ministry of Health website. March 16, 2022. Available at: https:\/\/www.gov.il\/he\/departments\/publications\/reports\/licenses-status-february-2022 (accessed August 16, 2022)."},{"key":"ref2","unstructured":"3. Medical Cannabis Unit of the Israel Ministry of Health. Presentation of current data from patient licenses - February 2022 [Hebrew]. Ministry of Health website. March 16, 2022. Available at: https:\/\/www.gov.il\/BlobFolder\/reports\/licenses-status-february-2022\/he\/licenses-status-february-2022.pdf (accessed August 16, 2022)."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/17512433.2021.1917379","article-title":"Cannabidiol in low back pain: scientific rationale for clinical trials in low back pain","volume":"14","author":"Xantus","year":"2021","unstructured":"4. Xantus G, Zvori L, Matheson C, Gyarmathy VA, Fazekas LM, Kanizasai P. Cannabidiol in low back pain: scientific rationale for clinical trials in low back pain. Expert Rev Clin Pharmacol 2021;14:671-5.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.2042-7158.1974.tb09306.x","article-title":"The cannabinoid content of Cannabis sativa L grown in England","volume":"26","author":"JW","year":"1974","unstructured":"5. Fairbairn JW, Liebmann JA. The cannabinoid content of Cannabis sativa L grown in England. J Pharm Pharmacol 1974;26:413-19.","journal-title":"J Pharm Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.tplants.2020.04.007","article-title":"Cannabis phytomolecule 'entourage': from domestication to medical use","volume":"25","author":"Koltai","year":"2020","unstructured":"6. Koltai H, Namdar D. Cannabis phytomolecule 'entourage': from domestication to medical use. Trends Plant Sci 2020;25:976-84.","journal-title":"Trends Plant Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.3390\/molecules26134080","article-title":"Essential oil of Cannabis sativa L: comparison of yield and chemical composition of 11 hemp genotypes","volume":"26","author":"Pieracci","year":"2021","unstructured":"7. Pieracci Y, Ascrizzi R, Terreni V, et al. Essential oil of Cannabis sativa L: comparison of yield and chemical composition of 11 hemp genotypes. Molecules 2021; 26:4080.","journal-title":"Molecules"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fpls.2019.00614","article-title":"The complex interactions between flowering behavior and fiber quality in hemp","volume":"10","author":"Salentijn","year":"2019","unstructured":"8. Salentijn EMJ, Petit J, Trindade LM. The complex interactions between flowering behavior and fiber quality in hemp. Front Plant Sci 2019;10:614.","journal-title":"Front Plant Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"613805","DOI":"10.3389\/fphar.2021.613805","article-title":"Prolonged medical cannabis treatment is associated with quality of life improvement and reduction of analgesic medication consumption in chronic pain patients","volume":"12","author":"Aviram","year":"2021","unstructured":"9. Aviram J, Lewitus GM, Vysotski Y, et al. Prolonged medical cannabis treatment is associated with quality of life improvement and reduction of analgesic medication consumption in chronic pain patients. Front Pharmacol 2021;12:613805.","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/JCP.0000000000001089","article-title":"The potential for pharmacokinetic interactions between cannabis products and conventional medications","volume":"39","author":"Qian","year":"2019","unstructured":"10. Qian Y, Gurley BJ, Markowitz JS. The potential for pharmacokinetic interactions between cannabis products and conventional medications. J Clin Psychopharmacol 2019;39:462-71.","journal-title":"J Clin Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jpain.2021.04.011","article-title":"Substituting cannabidiol for opioids and pain medications among individuals with fibromyalgia: a large online survey","volume":"22","author":"Boehnke","year":"2021","unstructured":"11. Boehnke KF, Gagnier JJ, Matallana L, Williams DA. Substituting cannabidiol for opioids and pain medications among individuals with fibromyalgia: a large online survey. J Pain 2021;22:1418-28.","journal-title":"J Pain"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1089\/can.2019.0039","article-title":"The impact of medical cannabis on intermittent and chronic opioid users with back pain: how cannabis diminished prescription opioid usage","volume":"5","author":"Takakuwa","year":"2020","unstructured":"12. Takakuwa KM, Hergenrather JY, Shofer FS, Schears RM. The impact of medical cannabis on intermittent and chronic opioid users with back pain: how cannabis diminished prescription opioid usage. Cannabis Cannabinoid Res 2020;5:263-70.","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"827849","DOI":"10.3389\/fmed.2022.827849","article-title":"Adherence, safety, and effectiveness of medical cannabis and epidemiological characteristics of the patient population: a prospective study","volume":"9","author":"Bar-Lev Schleider","year":"2022","unstructured":"13. Bar-Lev Schleider L, Mechoulam R, Sikorin I, Naftali T, Novack V. Adherence, safety, and effectiveness of medical cannabis and epidemiological characteristics of the patient population: a prospective study. Front Med (Lausanne) 2022;9:827849.","journal-title":"Front Med (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s42238-021-00116-7","article-title":"A mixed methods analysis of cannabis use routines for chronic pain management","volume":"4","author":"Boehnke","year":"2022","unstructured":"14. Boehnke KF, Yakas L, Scott JR, et al. A mixed methods analysis of cannabis use routines for chronic pain management. J Cannabis Res 2022;4:7.","journal-title":"J Cannabis Res"},{"key":"ref14","unstructured":"15. Faculty of Pain Medicine of the Royal College of Anaesthetists. Dose equivalents and changing opioids. Available at: https:\/\/fpm.ac.uk\/opioids-aware-structured-approach-opioid-prescribing\/dose-equivalents-and-changing-opioids (accessed September 4, 2022)."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1007\/s00213-021-05976-8","article-title":"Pharmacokinetic and pharmacodynamic properties of aerosolized (\"vaped\") THC in adolescent male and female rats","volume":"238","author":"Ruiz","year":"2021","unstructured":"16. Ruiz CM, Torrens A, Lallai V, et al. Pharmacokinetic and pharmacodynamic properties of aerosolized (\"vaped\") THC in adolescent male and female rats. Psychopharmacology (Berl) 2021;238:3595-605.","journal-title":"Psychopharmacology (Berl)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-3-030-61663-2_3","article-title":"Clinical pharmacokinetics of cannabinoids and potential drug-drug interactions","volume":"1297","author":"V\u00e1zquez","year":"2021","unstructured":"17. V\u00e1zquez M, Garc\u00eda-Carnelli C, Maldonado C, Fagiolino P. Clinical pharmacokinetics of cannabinoids and potential drug-drug interactions. Adv Exp Med Biol 2021;1297:27-42.","journal-title":"Adv Exp Med Biol"},{"key":"ref17","unstructured":"18. Ware JE Jr, Kosinski M, Keller SD. SF-12: How to Score the SF-12 Physical and Mental Health Summary Scales. 2nd ed. Boston, MA: The Health Institute, New England Research Center; 1995."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/BMR-160726","article-title":"Psychometric properties of the Hebrew version of the Oswestry Disability Index","volume":"30","author":"Gamus","year":"2017","unstructured":"19. Gamus D, Glasser S, Langner E, et al. Psychometric properties of the Hebrew version of the Oswestry Disability Index. J Back Musculoskelet Rehabil 2017; 30:135-43.","journal-title":"J Back Musculoskelet Rehabil"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.pmn.2006.09.001","article-title":"Determination of clinically meaningful levels of pain reduction in patients experiencing acute postoperative pain","volume":"7","author":"Sloman","year":"2006","unstructured":"20. Sloman R, Woloski Wruble A, Rosen G, Rom M. Determination of clinically meaningful levels of pain reduction in patients experiencing acute postoperative pain. Pain Manag Nurs 2006;7:153-8.","journal-title":"Pain Manag Nurs"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/sim.8009","article-title":"Allowing for uncertainty due to missing and LOCF imputed outcomes in meta-analysis","volume":"38","author":"Mavridis","year":"2019","unstructured":"21. Mavridis D, Salanti G, Furukawa TA, Cipriani A, Chaimani A, White IR. Allowing for uncertainty due to missing and LOCF imputed outcomes in meta-analysis. Stat Med 2019;38:720-37.","journal-title":"Stat Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1089\/can.2019.0077","article-title":"Cannabis use and low-back pain: a systematic review","volume":"5","author":"First","year":"2020","unstructured":"22. First L, Douglas W, Habibi B, Singh JR, Sein MT. Cannabis use and low-back pain: a systematic review. Cannabis Cannabinoid Res 2020;5:283-9.","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref22","unstructured":"23. Yassin M, Oron A, Robinson D. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. Clin Exp Rheumatol 2019;37(Suppl 116):13-20. PMID: 30418116"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1503\/cjs.001018","article-title":"Cannabis for pain in orthopedics: a systematic review focusing on study methodology","volume":"62","author":"Madden","year":"2019","unstructured":"24. Madden K, George A, van der Hoek NJ, Borim FM, Mammen G, Bhandari M. Cannabis for pain in orthopedics: a systematic review focusing on study methodology. Can J Surg 2019;62:369-80.","journal-title":"Can J Surg"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/jphp.12845","article-title":"Cannabinoids concentration variability in cannabis olive oil galenic preparations","volume":"70","author":"Carcieri","year":"2018","unstructured":"25. Carcieri C, Tomasello C, Simiele M, et al. Cannabinoids concentration variability in cannabis olive oil galenic preparations. J Pharm Pharmacol 2018;70: 143-9.","journal-title":"J Pharm Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/ijpp.12514","article-title":"Spontaneous, anecdotal, retrospective, open-label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan)","volume":"27","author":"Palmieri","year":"2019","unstructured":"26. Palmieri B, Laurino C, Vadal\u00e0 M. Spontaneous, anecdotal, retrospective, open-label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan). Int J Pharm Pract 2019;27:264-70.","journal-title":"Int J Pharm Pract"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Russo EB, Cuttler C, Cooper ZD, Stueber A, Whiteley VL, Sexton M. Survey of patients employing cannabigerol-predominant cannabis preparations: perceived medical effects, adverse events, and withdrawal symptoms. Cannabis Cannabinoid Res 2021 Sep 27. Online ahead of print.","DOI":"10.1089\/can.2021.0058"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/j.pain.0000000000002463","article-title":"Sex differences in medical cannabis-related adverse effects","volume":"163","author":"Aviram","year":"2022","unstructured":"28. Aviram J, Lewitus GM, Vysotski Y, et al. Sex differences in medical cannabis-related adverse effects. Pain 2022;163:975-83.","journal-title":"Pain"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s12178-022-09743-w","article-title":"Analyzing the impact of cannabinoids on the treatment of spinal disorders","volume":"15","author":"Shah","year":"2022","unstructured":"29. Shah RM, Saklecha A, Patel AA, Divi SN. Analyzing the impact of cannabinoids on the treatment of spinal disorders. Curr Rev Musculoskelet Med 2022;15:133-42.","journal-title":"Curr Rev Musculoskelet Med"},{"key":"ref29","unstructured":"30. National Institute for Health and Care Excellence (NICE). Cannabis-based medicinal products. [B] Evidence review for chronic pain. NICE guideline NG144. Evidence review underpinning recommendations 1.2.1 to 1.2.3 in the NICE guideline. November 2019. Available at: https:\/\/www.nice.org.uk\/guidance\/ng144\/evidence\/b-chronic-pain-pdf-6963831759 (accessed September 5, 2022)."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2147\/JPR.S98182","article-title":"Medical cannabis - the Canadian perspective","volume":"9","author":"GD","year":"2016","unstructured":"31. Ko GD, Bober SL, Mindra S, Moreau JM. Medical cannabis - the Canadian perspective. J Pain Res 2016; 9:735-44.","journal-title":"J Pain Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000521492","article-title":"Medicinal cannabis for the treatment of chronic refractory pain: an investigation of the adverse event profile and health-related quality of life impact of an oral formulation","volume":"5","author":"Abelev","year":"2022","unstructured":"32. Abelev S, Warne LN, Benson M, Hardy M, Nayee S, Barlow J. Medicinal cannabis for the treatment of chronic refractory pain: an investigation of the adverse event profile and health-related quality of life impact of an oral formulation. Med Cannabis Cannabinoids 2022;5:20-31.","journal-title":"Med Cannabis Cannabinoids"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/1442\/2\/PublishFiles\/1518Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:35:03Z","timestamp":1730813703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/55\/articles\/1518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,27]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10485","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}